Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1-Reference-Cited by-同舟云学术

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:384-387
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chari Ajai¹,Touzeau Cyrille²,Schinke Carolina³,Minnema Monique C.⁴,Berdeja Jesus⁵,Oriol Albert⁶,Van De Donk Niels WCJ⁷,Rodriguez Otero Paula⁸,Askari Elham⁹,Mateos Maria-Victoria¹⁰,Costa Luciano J.¹¹,Caers Jo¹²,Rasche Leo¹³,Krishnan Amrita Y.¹⁴,Vishwamitra Deeksha¹⁵,Ma Xuewen¹⁵,Qin Xiang¹⁵,Gries Katharine S.¹⁶,Campagna Michela¹⁷,Masterson Tara¹⁵,Hilder Brandi¹⁵,Tolbert Jaszianne¹⁵,Renaud Thomas¹⁸,Goldberg Jenna D.¹⁸,Heuck Christoph¹⁵,San-Miguel Jesús¹⁹,Moreau Philippe²⁰

Affiliation:

1. 1Mount Sinai School of Medicine, New York, NY

2. 2Centre Hospitalier Universitaire de Nantes, Nantes, France

3. 3Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR

4. 4University Medical Center Utrecht, Utrecht, Netherlands

5. 5Sarah Cannon Research Institute, Nashville, TN

6. 6Hospital Germans Trias I Pujol, Barcelona, Spain

7. 7Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

8. 8University of Navarra, Pamplona, Spain

9. 9Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

10. 10University Hospital of Salamanca/IBSAL/CIC, Salamanca, Spain

11. 11University of Alabama at Birmingham, Birmingham, AL